Legal Representation
Attorney
Jacqueline Lesser
USPTO Deadlines
Next Deadline
754 days remaining
Section 8 Declaration Due (Principal Register) (Based on registration date 20220125)
Due Date
January 25, 2028
Grace Period Ends
July 25, 2028
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
50 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Dec 1, 2025 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Dec 1, 2025 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
| Dec 1, 2025 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
| Apr 16, 2025 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Apr 16, 2025 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
| Apr 16, 2025 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
| Apr 16, 2025 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | Loading... |
| Apr 16, 2025 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED | Loading... |
| Dec 25, 2024 | ASGN | I | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | Loading... |
| May 17, 2023 | ASGN | I | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | Loading... |
| Jan 25, 2022 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Dec 24, 2021 | SUNA | E | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | Loading... |
| Dec 23, 2021 | CNPR | P | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | Loading... |
| Dec 23, 2021 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
| Dec 23, 2021 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
| Dec 23, 2021 | GNEA | O | EXAMINERS AMENDMENT E-MAILED | Loading... |
| Dec 23, 2021 | SNEA | W | SU-EXAMINER'S AMENDMENT WRITTEN | Loading... |
| Dec 21, 2021 | SUPC | I | STATEMENT OF USE PROCESSING COMPLETE | Loading... |
| Nov 12, 2021 | IUAF | S | USE AMENDMENT FILED | Loading... |
| Dec 13, 2021 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| Nov 12, 2021 | EISU | I | TEAS STATEMENT OF USE RECEIVED | Loading... |
| Nov 2, 2021 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Sep 7, 2021 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Sep 7, 2021 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Aug 18, 2021 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Aug 2, 2021 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Aug 2, 2021 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Jul 30, 2021 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Jul 29, 2021 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Jul 29, 2021 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Jul 1, 2021 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Jul 1, 2021 | GNRT | O | NON-FINAL ACTION E-MAILED | Loading... |
| Jul 1, 2021 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Jun 4, 2021 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Jun 3, 2021 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Jun 3, 2021 | ERSI | I | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | Loading... |
| Apr 13, 2021 | RCSC | S | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | Loading... |
| Oct 13, 2020 | RCSC | S | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | Loading... |
| Apr 9, 2020 | GNS3 | O | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | Loading... |
| Apr 9, 2020 | GNSL | S | LETTER OF SUSPENSION E-MAILED | Loading... |
| Apr 9, 2020 | CNSL | R | SUSPENSION LETTER WRITTEN | Loading... |
| Mar 11, 2020 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Mar 10, 2020 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Mar 10, 2020 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Oct 24, 2019 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | Loading... |
| Oct 24, 2019 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED | Loading... |
| Sep 12, 2019 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Sep 12, 2019 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Sep 12, 2019 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Sep 10, 2019 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
Detailed Classifications
Class 005
Monoclonal antibodies for use in disease testing; biological preparations for the treatment of cancer, tumor suppressing agents, anti-cancer preparations, and pharmaceutical preparations for the treatment of immune system related diseases and disorders, all comprising monoclonal antibodies
First Use Anywhere:
Apr 13, 2020
First Use in Commerce:
Apr 28, 2020
Class 042
Biomedical research services; conducting early evaluations in the field of new pharmaceuticals; quality control of goods and services; product quality testing; pharmaceutical product evaluation; biological research; conducting clinical trials for others that feature or contain monoclonal antibodies; research and development services in the field of antibodies
First Use Anywhere:
Apr 13, 2020
First Use in Commerce:
Apr 28, 2020
Additional Information
Design Mark
The mark consists of a blue and green stylized ring having a blue and dark blue left portion and a green and light green right portion. To the right of the ring is the word "I-MAB" written in dark blue upper case letters with a fading green arched cross-stroke extending from the left leg of the letter "A" through its center and extending through the center of the letter "B". Below the word "I-MAB" is the word "BIOPHARMA" written in dark blue upper case letters. The color white appearing in the mark represents transparent space and is not a part of the mark.
Color Claim
The color(s) blue, dark blue, green, and light green is/are claimed as a feature of the mark.
Classification
International Classes
005
042
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"BIOPHARMA"